[1]刘瑞芳,赵 华,史红娟,等.益生菌与2型糖尿病心血管疾病的研究进展[J].医学信息,2019,(18):29-31.[doi:10.3969/j.issn.1006-1959.2019.18.010]
 LIU Rui-fang,ZHAO Hua,SHI Hong-juan,et al.Advances in Research on Probiotics and Cardiovascular Diseases in Type 2 Diabetes[J].Medical Information,2019,(18):29-31.[doi:10.3969/j.issn.1006-1959.2019.18.010]
点击复制

益生菌与2型糖尿病心血管疾病的研究进展()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年18期
页码:
29-31
栏目:
综述
出版日期:
2019-09-15

文章信息/Info

Title:
Advances in Research on Probiotics and Cardiovascular Diseases in Type 2 Diabetes
文章编号:
1006-1959(2019)18-0029-03
作者:
刘瑞芳赵 华史红娟姚水洪
衢州职业技术学院,浙江 衢州 324000
Author(s):
LIU Rui-fangZHAO HuaSHI Hong-juanYAO Shui-hong
Quzhou Vocational and Technical College,Quzhou 324000,Zhejiang,China
关键词:
益生菌2型糖尿病心血管疾病
Keywords:
Key words:ProbioticsType 2 diabetesCardiovascular disease
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2019.18.010
文献标志码:
A
摘要:
糖尿病已成为严重威胁人类健康的世界性公共卫生问题,其中2型糖尿病发病率的增长远高于1型糖尿病。心血管疾病是2型糖尿病患者死亡的主要原因,血脂异常是2型糖尿病心血管并发症的危险因素。益生菌是一种活性微生物,越来越多的证据表明,补充益生菌可以预防和治疗心血管疾病,但具体临床应用效果仍存在争议。本文主要就益生菌与2型糖尿病心血管疾病的关系进行综述,以期为临床后续治疗提供参考。
Abstract:
Abstract:Diabetes has become a worldwide public health problem that poses a serious threat to human health. The incidence of type 2 diabetes is much higher than that of type 1 diabetes. Cardiovascular disease is the leading cause of death in patients with type 2 diabetes, and dyslipidemia is a risk factor for cardiovascular complications in type 2 diabetes. Probiotics are an active microorganism. There is increasing evidence that supplementation with probiotics can prevent and treat cardiovascular disease, but the specific clinical application effect remains controversial. This article reviews the relationship between probiotics and cardiovascular disease in type 2 diabetes, in order to provide reference for clinical follow-up treatment.

参考文献/References:

[1]Boden WE,Probstfield JL,Anderson T,et al.Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy[J].N Engl J Med,2011,365(24):2255-2267. [2]Kasubuchi M,Hasegawa S,Hiramatsu T,et al.Dietary gut microbial metabolites,short-chain fatty acids,and host metabolic regulation[J].Nutrients,2015,7(4):2839-2849. [3]Nagatomo Y,Tang WH.Intersections between microbiome and heart failure:Revisiting the gut hypothesis[J].J Card Fai,2015,21(12):973-980. [4]Brandao RL,Castro IM,Bambirra EA,et al.Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae[J].Appl Environ Microbiol,1998,64(2):564-568. [5]Guillot JF.Probiotic feed additives[J].J Vet Pharmacol Ther,2003(26):52-55. [6]Isolauri E,Sutas Y,Kankaanpaa P,et al.Probiotics:Effects on immunity[J].Am J Clin Nutr,2001,73(2 Suppl):444S-450S. [7]Thushara RM,Gangadaran S,Solati Z,et al.Cardiovascular benefifits of probiotics:a review of experimental and clinical studies[J].Food Funct,2016,7(2):632-642. [8]Hill C,Guarner F,Reid G,et al.Expert consensus document:The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic[J].Nat Rev Gastroenterol Hepatol,2014,11(8):506-514. [9]Schoster A,Kokotovic B,Permin A,et al.In Vitro inhibition of Clostridium difficile and Clostridium perfringens by commercial probiotic strains[J].Anaerobe,2013(20):36-41. [10]Chingwaru W,Vidmar J.Potential of Zimbabwean commercial probiotic products and strains of Lactobacillus plantarum as prophylaxis and therapy against diarrhoea caused by Escherichia coli in children[J].Asian Pac J Trop Med,2017,10(1):57-63. [11]Sikorska H,Smoragiewicz W.Role of probiotics in the prevention and treatment of ethicillin-resistant Staphylococcus aureus infections[J].Int J Antimicrob Agents,2013,42(6):475-481. [12]Li P,Gu Q.Complete genome sequence of Lactobacillus plantarum LZ95,a potential probiotic strain producing bacteriocins and B-group vitamin riboflavin[J].J Biotechnol,2016(229):1-2. [13]Nova E,Warnberg J,Gomez-Martinez S,et al.Immunodulatory effects of probiotics in different stages of life[J].Br J Nutr,2007,98(Suppl 1):S90-S95. [14]Mann GV.A factor in yogurt which lowers cholesteremia in man[J].Atherosclerosis,1977,26(3):335-340. [15]Nguyen TD,Kang JH,Lee MS.Characterization of lactobacillus plantarum PH04,a potential probiotic bacterium with cholesterol-lowering effects[J].Int J Food Microbiol,2007,113(3):358-361. [16]Sharma S,Kurpad AV,Puri S.Potential of probiotics in hypercholesterolemia:A meta-analysis[J].Indian J Public Health,2016,60(4):280-286. [17]Ito M,Kusuhara S,Yokoi W,et al.Streptococcus thermophilus fermented milk reduces serum MDA-LDL and blood pressure in healthy and mildly hypercholesterolaemic adults[J].Benefcial Microbes,2017,8(2):171-178. [18]Costabile A,Buttarazzi I,Kolida S,et al.An in vivo assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults[J].PLoS One,2017,12(12):e0187964. [19]Mariush TM,Ismail SH.Clinical Effects of Probiotic Supplementation on Type-2 Diabetic Iraqi Patients Associated with Dyslipidemia[J].J Phys Pharm Adv,2013,3(9):239-246. [20]解傲,袁杰利.双歧杆菌降胆固醇的作用机制[J].中国微生态学志,2014,26(4):493-495. [21]Lewis SJ,Burmeister S.A double-blind placebo-controlled study of the effects of lactobacillus acidophilus on plasma lipids[J].Eur J Clin Nutr,2005,59(6):776-780. [22]Simons LA,Amansec SG,Conway P.Effect of lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol[J].Nutr Metab Cardiovas,2006,16(8):531-535. [23]Guariguata L,Whiting DR,Hambleton I,et al.Global estimates of diabetes prevalence for 2013 and projections for 2035[J].Diabetes Res Clin Pract,2014,103(2):137-149. [24]Koutnikova H,Genser B,Monteiro-Sepulveda M,et al.Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables:a systematic review and meta-analysis of randomised controlled trials[J].BMJ Open,2019,9(3):e017995. [25]Ryan PM,Ross RP,Fitzgerald GF,et al.Functional food addressing heart health:Do we have to target the gut microbiota[J].Curr Opin Clin Nutr Metab Care,2015,18(6):566-571. [26]Sun J,Buys N.Effects of probiotics consumption on lowering lipids and CVD risk factors:A systematic review and meta-analysis of randomized controlled trials[J].Ann Med,2015,47(6):430-440. [27]Hua LM.Type 2 diabetes and probiotics, prebiotics and synbiotics:a meta-analysis[J].Chin J Microecol,2016(28):1257-1268. [28]Li C,Li X,Han H,et al.Effect of probiotics on metabolic profiles in type 2 diabetes mellitus: a meta-analysis of randomized,controlled trials[J].Medicine,2016,95(26):e4088. [29]Bayat A,Azizi-Soleiman F,Heidari-Beni M,et al.Effect of cucurbita ficifolia and probiotic yogurt consumption on blood glucose,lipid profile,and inflammatory marker in type 2 diabetes[J].Int J Prev Med,2016(7):30. [30]Hendijani F,Akbari V.Probiotic supplementation for management of cardiovascular risk factors in adults with type Ⅱdiabetes:A systematic review and meta-analysis[J].Clin Nutr,2018,37(2):532-541. [31]Ostadrahimi A,Taghizadeh A,Mobasseri M,et al.Effect of probiotic fermented milk(kefir)on glycemic control and lipid profile in type 2 diabetic patients:a randomized double -blind placebo- controlled clinical trial[J].Iran J Public Health,2015,44(2):228-237. [32]Hsieh MC,Tsai WH,Jheng YP,et al.The benefcial efects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus:a randomized,double blinded,placebo-controlled trial[J].Scientific Reports,2018,8(1):16791.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
 HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Medical Information,2018,(18):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
 DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Medical Information,2018,(18):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
 CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Medical Information,2018,(18):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
 JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Medical Information,2018,(18):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
 LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Medical Information,2018,(18):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行 健康管理模式的研究[J].医学信息,2018,(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
 LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Medical Information,2018,(18):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
[7]丁 星,赵 畅,张海严,等.麦邦数据远程传输型血糖仪临床测量准确性的评价研究[J].医学信息,2018,(15):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
 DING Xing,ZHAO Chang,ZHANG Hai-yan,et al.Evaluation of Accuracy of Clinical Measurement of Maibang Remote Data Transmission Glucometer[J].Medical Information,2018,(18):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
[8]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
 LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2018,(18):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[9]刘小红.长效胰岛素联合口服降糖药治疗2型糖尿病的 疗效与安全性评价[J].医学信息,2018,(18):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
 LIU Xiao-hong.Efficacy and Safety of Long Acting Insulin Combined with Oral Hypoglycemic Agents in Treatment of Type 2 Diabetes Mellitus[J].Medical Information,2018,(18):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
[10]鲍 哲,杨升伟,柯赛赛,等.益生元对2型糖尿病患者糖脂代谢的影响[J].医学信息,2018,(18):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]
 BAO Zhe,YANG Sheng-wei,KE Sai-sai,et al.Effect of Prebiotics on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes mellitus[J].Medical Information,2018,(18):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]

更新日期/Last Update: 2019-09-15